Another study by Cerisoli et al. [8], comparing the phenotype and ‘inflammatory’ miRNA EV cargo from patients with low-risk MDS and healthy individuals, revealed a significantly higher EV CD34 expression in MDS patients, which did not correlate with blast percentage and did not predict disease progression. The gene discussed is CD34; the disease is myelodysplastic syndrome.